M. Tuberculosis 85-B Antigen (DAGA-185)

M. Tuberculosis 85-B Antigen, Recombinant protein from E. coli for WB, ELISA

Product Overview
C-terminal 6xHis fusion protein of antigen 85-B (Rv1886c) (M. Tuberculosis/H37Rv)(a.a.1-329) (Genbank Accession No. NP_216402).Secreted antigen 85-B FbpB (85B) (antigen 85 complex B) (mycolyltransferase 85B) (fibronectin-binding protein B) (extracellular alpha-antigen). Predicted possible vaccine candidate.
Nature
Recombinant
Tag/Conjugate
Unconjugated
Alternative Names
M. Tuberculosis 63 kDa protein; Mycobacterium tuberculosis 97 kDa protein; Mycobacterium tuberculosis; M. tuberculosis; MTB; TB antigen
Procedure
None
Purity
>95% , based on SDS PAGE
Format
Each vial contains 100 µg of lyophilized protein in PBS with 8M Urea.
Concentration
Batch dependent - please inquire should you have specific requirements.
Size
1000ug, 1mg
Preservative
None
Reconstitution
Reconstitute the protein with 100 µl of Millipore water.
Antigen Description
Mycobacterium tuberculosis is an obligate pathogenic bacterial species in the family Mycobacteriaceae and the causative agent of tuberculosis First discovered in 1896 by Robert Koch, M. tuberculosis has an unusual, waxy coating on its cell surface (primar
Keywords
M. Tuberculosis 63 kDa protein;Mycobacterium tuberculosis 97 kDa protein;Mycobacterium tuberculosis;M. tuberculosis;MTB;TB antigen

Citations


Have you cited DAGA-185 in a publication? Let us know and earn a reward for your research.

Customer Reviews


Write a review, share your experiences with others and get rewarded !
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket

References


Inflammatory response is modulated by lincRNACox2 via the NF-kappa B pathway in macrophages infected by Mycobacterium tuberculosis

MOLECULAR MEDICINE REPORTS

Authors: Li, Danye; Gao, Caiyan; Zhao, Ling; Zhang, Yongming

Long intergenic non-coding RNAs (lincRNAs) are long non-coding transcripts from the intergenic regions of annotated protein-coding genes. lincRNA cyclooxygenase 2 (Cox2) is an early-primary response gene regulated by the NF-kappa B signaling pathway in macrophages. It was found that lincRNACox2 was significantly increased in patients with the Mycobacterium tuberculosis (M. tuberculosis) H37Ra strain infection and macrophages, using reverse transcription-quantitative PCR (RT-qPCR). ELISA, western blotting and RT-qPCR results indicated that the inflammatory response factors tumor necrosis factor-alpha, interferon-gamma, interleukin-6, Cox2 and inducible nitric oxide synthase were significantly increased in H37Ra infected macrophages. In addition, the inflammatory regulating proteins NF-kappa B and Stat3 were significantly increased in H37Ra infected macrophages but decreased in lincRNACox2 knockdown macrophages infected with H37Ra. Moreover, the knockdown of lincRNACox2 increased the apoptotic rate of H37Ra infected macrophages and facilitated the proliferation of H37Ra. Collectively, the present results suggested that lincRNACox2 may be required for the activation of NF-kappa B and Stat3, in order to regulate inflammatory responses involved in resistance to M. tuberculosis infection.

Evaluation of IL-1 Blockade as an Adjunct to Linezolid Therapy for Tuberculosis in Mice and Macaques

FRONTIERS IN IMMUNOLOGY

Authors: Winchell, Caylin G.; Mishra, Bibhuti B.; Phuah, Jia Yao; Saqib, Mohd; Nelson, Samantha J.; Maiello, Pauline; Causgrove, Chelsea M.; Ameel, Cassaundra L.; Stein, Brianne; Borish, H. Jacob; White, Alexander G.; Klein, Edwin C.; Zimmerman, Matthew D.; Dartois, Veronique; Lin, Philana Ling; Sassetti, Christopher M.; Flynn, JoAnne L.

In 2017 over 550,000 estimated new cases of multi-drug/rifampicin resistant tuberculosis (MDR/RR-TB) occurred, emphasizing a need for new treatment strategies. Linezolid (LZD) is a potent antibiotic for drug-resistant Gram-positive infections and is an effective treatment for TB. However, extended LZD use can lead to LZD-associated host toxicities, most commonly bone marrow suppression. LZD toxicities may be mediated by IL-1, an inflammatory pathway important for early immunity during M. tuberculosis infection. However, IL-1 can contribute to pathology and disease severity late in TB progression. Since IL-1 may contribute to LZD toxicity and does influence TB pathology, we targeted this pathway with a potential host-directed therapy (HDT). We hypothesized LZD efficacy could be enhanced by modulation of IL-1 pathway to reduce bone marrow toxicity and TB associated-inflammation. We used two animal models of TB to test our hypothesis, a TB-susceptible mouse model and clinically relevant cynomolgus macaques. Antagonizing IL-1 in mice with established infection reduced lung neutrophil numbers and partially restored the erythroid progenitor populations that are depleted by LZD. In macaques, we found no conclusive evidence of bone marrow suppression associated with LZD, indicating our treatment time may have been short enough to avoid the toxicities observed in humans. Though treatment was only 4 weeks (the FDA approved regimen at the time of study), we observed sterilization of the majority of granulomas regardless of co-administration of the FDA-approved IL-1 receptor antagonist (IL-1Rn), also known as Anakinra. However, total lung inflammation was significantly reduced in macaques treated with IL-1Rn and LZD compared to LZD alone. Importantly, IL-1Rn administration did not impair the host response against Mtb or LZD efficacy in either animal model. Together, our data support that inhibition of IL-1 in combination with LZD has potential to be an effective HDT for TB and the need for further research in this area.

Online Inquiry

Name:
Phone: *
E-mail Address: *
Technology Interest:
Type of Organization:
Service & Products Interested: *
Project Description:

Related Products

Related Resources

Ordering Information

Payment methods we support:
Invoice / Purchase Order
Credit card

Inquiry Basket